Pharmaceutical

Filter

Current filters:

None

Popular Filters

64 to 88 of 7145 results

UK Cancer Drugs Fund to re-assess procedure and currently-approved drugs

UK Cancer Drugs Fund to re-assess procedure and currently-approved drugs

13-11-2014

The UK’s National Health Service has updated its procedure for evaluating drugs in the Cancer Drugs…

AvastinKadcylaOncologyPharmaceuticalRegulationSprycelUK

FDA approves sNDA for Janssen's Invega Sustenna in schizoaffective disorder

FDA approves sNDA for Janssen's Invega Sustenna in schizoaffective disorder

13-11-2014

The US Food and Drug Administration has approved the supplemental New Drug Applications (sNDAs) from…

Invega SustennaJanssenNeurologicalPharmaceuticalRegulationUSA

Actavis' sNDA accepted by FDA for Saphris in bipolar I disorder

Actavis' sNDA accepted by FDA for Saphris in bipolar I disorder

13-11-2014

Ireland-headquartered generics major Actavis has had its Supplemental New Drug Application for Saphris…

ActavisIrelandNeurologicalPharmaceuticalRegulationSaphris

Dynamic growth of pharmaceutical sales to hospitals in Poland

Dynamic growth of pharmaceutical sales to hospitals in Poland

13-11-2014

The year 2013 was better for the Polish pharmaceutical distribution market than 2012, when wholesale…

Markets & MarketingPharmaceuticalPMRPolandPricing

Ukraine plans to ban drug imports from Russia

Ukraine plans to ban drug imports from Russia

13-11-2014

The Ukrainian government is considering imposing a ban on the import of drugs from Russia. This comes…

Markets & MarketingPharmaceuticalPoliticsRussiaUkraine

Takeda joins forces with GE Healthcare on liver disease research

Takeda joins forces with GE Healthcare on liver disease research

13-11-2014

Japan’s largest drugmaker Takeda Pharmaceutical has entered into an alliance agreement with UK-based…

GE HealthcareJapanNephrology and HepatologyPharmaceuticalResearchTakeda Pharmaceutical

Par Pharmaceuticals receives FDA approval for Vasostrict in low blood pressure

Par Pharmaceuticals receives FDA approval for Vasostrict in low blood pressure

13-11-2014

Generic and branded specialty pharma company Par Pharmaceuticals has received approval for its New Drug…

HematologyPar PharmaceuticalsPharmaceuticalRegulationUSAVasostrict

Ulcerative colitis market to hit $4.2 billion by 2023

Ulcerative colitis market to hit $4.2 billion by 2023

13-11-2014

The ulcerative colitis market is set to grow from $2.7 billion in 2013 to $4.2 billion in 2023 in the…

Decision Resources GroupEntyvioGastro-intestinalsGlobalMarkets & MarketingPharmaceuticalRemicadeResearchXeljanz

Merck KGaA raises forecasts on solid third-quarter 2014

Merck KGaA raises forecasts on solid third-quarter 2014

13-11-2014

German pharma and chemicals firm Merck KGaA this morning reported that revenue for the third quarter…

FinancialGermanyMerck KGaAMerck SeronoPharmaceutical

SMC accepts Eylea and Onglyza for use in NHS Scotland

SMC accepts Eylea and Onglyza for use in NHS Scotland

13-11-2014

The Scottish Medicines Consortium (SMC) has accepted German drugmaker Bayer’s Eylea (aflibercept solution…

AstraZenecaBayerDiabetesEyleaOnglyzaPharmaceuticalRegulationUK

UPDATE: UK agrees “Patent Box” compromise with Germany

UPDATE: UK agrees “Patent Box” compromise with Germany

13-11-2014

Germany and the UK have agreed a joint proposal to advance the negotiations on new rules for preferential…

FinancialGermanyPatentsPharmaceuticalPoliticsUK

GlaxoSmithKline files for added Revolade indication in EU

12-11-2014

UK pharma major GlaxoSmithKline has filed an application with the European Medicines Agency for a variation…

EuropeGlaxoSmithKlineLigand PharmaceuticalsOncologyPharmaceuticalPromactaRare diseasesRegulationRevolade

Boehringer Ingelheim start Phase III trial on idarucizumab as antidote to Pradaxa

Boehringer Ingelheim start Phase III trial on idarucizumab as antidote to Pradaxa

12-11-2014

German family-owned drug major Boehringer Ingelheim has initiated a global Phase III study on idarucizumab,…

Boehringer IngelheimHematologyidarucizumabPharmaceuticalPradaxaResearch

Actavis appoints Maria Teresa Hilado as chief financial officer

Actavis appoints Maria Teresa Hilado as chief financial officer

12-11-2014

Ireland-headquartered generics major Actavis has appointed Maria Teresa (Tessa) Hilado as chief financial…

ActavisBoardroomCFOIrelandPharmaceutical

Merck's Phase II trial of grazoprevir/elbasvir in hepatitis C genotype 1 positive

Merck's Phase II trial of grazoprevir/elbasvir in hepatitis C genotype 1 positive

12-11-2014

Pharma giant Merck & Co has presented results from its Phase II trial of grazoprevir/elbasvir, with or…

grazoprevir/elbasvirMerck & CoNephrology and HepatologyPharmaceuticalResearchUSA

Polyphor’s POL7080 receives QIDP designation from the FDA

12-11-2014

Privately-held Swiss pharma firm Polyphor says that the US Food and Drug Administration has designated…

Antibiotics and Infectious diseasesPharmaceuticalPOL7080PolyphorRegulationRocheUSA

Global melanoma market set to reach $3.6 billion by 2020

12-11-2014

The global melanoma therapeutics market was valued at $1.3 billion in 2013 and will expand at a compound…

Bristol-Myers SquibbEuropeJapanKeytrudaMarkets & MarketingMerck & CoOncologyOpdivoPharmaceuticalUSAYervoy

Afaxys announces wider US availability of ella emergency contraceptive

12-11-2014

US drugmaker Afaxys Pharmaceuticals, a division of Afaxys Inc, has announced wider US availability of…

AfaxysellaHRA PharmaMarkets & MarketingPharmaceuticalReproductiveUSAWomen's Health

GSK COPD survey shows many sufferers underestimate the severity of their condition

GSK COPD survey shows many sufferers underestimate the severity of their condition

12-11-2014

UK pharma major GlaxoSmithKline has conducted a global survey of people living with chronic obstructive…

GlobalGSKPharmaceuticalResearchRespiratory and PulmonaryUnited States

Durect to ‘refine the path’ of Posidur program

Durect to ‘refine the path’ of Posidur program

12-11-2014

US drugmaker Durect Corporation says that it has received meeting minutes from its face-to-face meeting…

AnalgesiaDurectPharmaceuticalPosidurRegulationUSA

New data show strong cure rates with AbbVie’s hep C therapy in HIV and transplant patient studies

New data show strong cure rates with AbbVie’s hep C therapy in HIV and transplant patient studies

11-11-2014

US pharma company AbbVie got a boost for its upcoming hepatitis C treatment regimen, with the company…

AbbVieAnti-viralsPharmaceuticalResearchUSA

Positive Ph III results with Highland Therapeutics’ HLD-200 in ADHD

11-11-2014

Ironshore Pharmaceuticals & Development, part of Canada-based specialty pharma company Highland Therapeutics,…

Highland TherapeuticsHLD-200Ironshore PharmaceuticalsMethylphenidate HclNeurologicalPharmaceuticalResearch

Biologics will complement statins in cholesterol treatment space, says GlobalData

Biologics will complement statins in cholesterol treatment space, says GlobalData

11-11-2014

Biologics will play an influential role in shaping the future of cardiovascular drug treatment, in particular…

alirocumabAmgenCardio-vascularevolocumabMarkets & MarketingPharmaceuticalRegeneronSanofiUSA

64 to 88 of 7145 results

Back to top